Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Bioanalysis

• Publication date

  2012-03-07

• Fields of study

  Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.4155/bio.11.334PMID 22394141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Addressing MIST (Metabolites in Safety Testing): bioanalytical approaches to address metabolite exposures in humans and animals.

  2011cited by this paper
• Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.

  2010cited by this paper
• NMR spectroscopy as a tool to close the gap on metabolite characterization under MIST.

  2010cited by this paper
• Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum.

  2010cited by this paper
• Novel MS solutions inspired by MIST.

  2010cited by this paper
• Challenges and solutions to metabolites in safety testing: impact of the International Conference on Harmonization M3(R2) guidance

  2010cited by this paper
• Looking back through the MIST: a perspective of evolving strategies and key focus areas for metabolite safety analysis.

  2010cited by this paper
• A radiocalibration method with pseudo internal standard to estimate circulating metabolite concentrations.

  2010cited by this paper
• Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.

  2009cited by this paper
• Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.

  2009cited by this paper
• Predicting circulating human metabolites: how good are we?

  2009cited by this paper
• Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS).

  2009cited by this paper
• Issues in the safety testing of metabolites.

  2009cited by this paper
• Subattomole sensitivity in biological accelerator mass spectrometry.

  2008cited by this paper
• Response normalized liquid chromatography nanospray ionization mass spectrometry

  2007cited by this paper
• What is the Objective of the Mass Balance Study? A Retrospective Analysis of Data in Animal and Human Excretion Studies Employing Radiolabeled Drugs

  2007cited by this paper
• AMS in drug development at GSK

  2007cited by this paper
• The Application of Accelerator Mass Spectrometry to Absolute Bioavailability Studies in Humans: Simultaneous Administration of an Intravenous Microdose of 14C‐Nelfinavir Mesylate Solution and Oral Nelfinavir to Healthy Volunteers

  2005cited by this paper
• Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor.

  2002cited by this paper
• Drug metabolites in safety testing.

  2002cited by this paper
• Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique

  2001cited by this paper
• Recent advances in the applications of radioisotopes in drug metabolism, toxicology and pharmacokinetics.

  2000cited by this paper
• Accelerator mass spectrometry in pharmaceutical research and development--a new ultrasensitive analytical method for isotope measurement.

  2000cited by this paper
• Studies on the metabolism of fluorinated xenobiotics in the rat using 19F-NMR and 1H-NMR spectroscopy.

  1990cited by this paper

• Human absorption, distribution, metabolism, and excretion studies: Conventional or microtracer?

  2025cites this paper
• Considerations for Human ADME Strategy and Design Paradigm Shift(s) – An Industry White Paper

  2022cites this paper
• Evaluation of cAMS for 14C microtracer ADME studies: opportunities to change the current drug development paradigm.

  2018cites this paper
• Species differences in bile acids II. Bile acid metabolism

  2018cites this paper
• In-Vitro and In-Vivo Models of Bile Acid Metabolism and Transport

  2017influential citation
• Lack of Exposure in a First-in-Man Study Due to Aldehyde Oxidase Metabolism: Investigated by Use of 14C-microdose, Humanized Mice, Monkey Pharmacokinetics, and In Vitro Methods

  2017cites this paper
• Adding value through accelerator mass spectrometry-enabled first in human studies.

  2016cites this paper
• UNDERSTANDING DRUG METABOLISM IN HUMANS

  2016cites this paper
• Application of (14)C-accelerator MS in pharmaceutical development.

  2015cites this paper
• Comparison of minipig, dog, monkey and human drug metabolism and disposition.

  2015cites this paper
• To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics

  2015cites this paper
• Opportunities in low-level radiocarbon microtracing: applications and new technology

  2015cites this paper
• Pragmatic approaches to determine the exposures of drug metabolites in preclinical and clinical subjects in the MIST evaluation of the clinical development phase.

  2014cites this paper
• Application of a tiered approach to the validation of accelerator MS assays.

  2014cites this paper
• Disposition and Metabolism of Darapladib , a Lipoprotein-Associated Phospholipase A 2 Inhibitor , in Humans

  2014cites this paper
• Reflecting on a decade of metabolite screening and monitoring.

  2014cites this paper
• Disposition and Metabolism of Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Humans

  2014cites this paper
• The debate on animal ADME studies in drug development: an update

  2014cites this paper